Scorpius Holdings, Inc., a pharmaceutical company with a market capitalization of $1.36 million, has entered into a material definitive agreement through the issuance of a non-convertible ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American:SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

In a recent SEC filing, Scorpius Holdings, Inc. (SCPX), a pharmaceutical company with a market capitalization of $780,000, disclosed amendments to the employment agreements of two key executives. The ...

Scorpius Holdings, Inc. (NYSE American: SCPX), a pharmaceutical company with a market capitalization of $0.78 million, announced the expansion of its Board of Directors and the appointment of a new ...

Scorpius Holdings (SCPX) has engaged Alliance Global Partners to assist in exploring strategic alternatives for the Company. This engagement is part of the Company’s ongoing efforts to maximize ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), ...